Sub-dominant principal components inform new vaccine targets for HIV Gag
- PMID: 31250884
- DOI: 10.1093/bioinformatics/btz524
Sub-dominant principal components inform new vaccine targets for HIV Gag
Abstract
Motivation: Patterns of mutational correlations, learnt from patient-derived sequences of human immunodeficiency virus (HIV) proteins, are informative of biochemically linked networks of interacting sites that may enable viral escape from the host immune system. Accurate identification of these networks is important for rationally designing vaccines which can effectively block immune escape pathways. Previous computational methods have partly identified such networks by examining the principal components (PCs) of the mutational correlation matrix of HIV Gag proteins. However, driven by a conservative approach, these methods analyze the few dominant (strongest) PCs, potentially missing information embedded within the sub-dominant (relatively weaker) ones that may be important for vaccine design.
Results: By using sequence data for HIV Gag, complemented by model-based simulations, we revealed that certain networks of interacting sites that appear important for vaccine design purposes are not accurately reflected by the dominant PCs. Rather, these networks are encoded jointly by both dominant and sub-dominant PCs. By incorporating information from the sub-dominant PCs, we identified a network of interacting sites of HIV Gag that associated very strongly with viral control. Based on this network, we propose several new candidates for a potent T-cell-based HIV vaccine.
Availability and implementation: Accession numbers of all sequences used and the source code scripts for all analysis and figures reported in this work are available online at https://github.com/faraz107/HIV-Gag-Immunogens.
Supplementary information: Supplementary data are available at Bioinformatics online.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.Vaccine. 2013 Jun 24;31(29):3000-8. doi: 10.1016/j.vaccine.2013.04.057. Epub 2013 May 10. Vaccine. 2013. PMID: 23664989
-
QUASI analysis of host immune responses to Gag polyproteins of human immunodeficiency virus type 1 by a systematic bioinformatics approach.Biochem Cell Biol. 2010 Aug;88(4):671-81. doi: 10.1139/O10-002. Biochem Cell Biol. 2010. PMID: 20651839
-
Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29. J Virol. 2015. PMID: 25355891 Free PMC article.
-
Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo.Hum Gene Ther. 2008 Jun;19(6):622-34. doi: 10.1089/hum.2007.095. Hum Gene Ther. 2008. PMID: 18533892
-
Justification for the inclusion of Gag in HIV vaccine candidates.Expert Rev Vaccines. 2016 May;15(5):585-98. doi: 10.1586/14760584.2016.1129904. Epub 2015 Dec 28. Expert Rev Vaccines. 2016. PMID: 26645951 Review.
Cited by
-
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.Adv Drug Deliv Rev. 2021 Apr;171:29-47. doi: 10.1016/j.addr.2021.01.007. Epub 2021 Jan 17. Adv Drug Deliv Rev. 2021. PMID: 33465451 Free PMC article. Review.
-
Design of multivalent-epitope vaccine models directed toward the world's population against HIV-Gag polyprotein: Reverse vaccinology and immunoinformatics.PLoS One. 2024 Sep 27;19(9):e0306559. doi: 10.1371/journal.pone.0306559. eCollection 2024. PLoS One. 2024. PMID: 39331650 Free PMC article.
-
HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies.Virus Evol. 2023 Nov 18;9(2):vead068. doi: 10.1093/ve/vead068. eCollection 2023. Virus Evol. 2023. PMID: 38107333 Free PMC article.
-
Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a.iScience. 2021 Dec 8;25(1):103569. doi: 10.1016/j.isci.2021.103569. eCollection 2022 Jan 21. iScience. 2021. PMID: 34988406 Free PMC article.
-
Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis.Nat Commun. 2023 Nov 17;14(1):7457. doi: 10.1038/s41467-023-42550-6. Nat Commun. 2023. PMID: 37978179 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical